4.7 Article

European expert opinion on the management of invasive candidiasis in adults

Journal

CLINICAL MICROBIOLOGY AND INFECTION
Volume 17, Issue -, Pages 1-12

Publisher

ELSEVIER SCI LTD
DOI: 10.1111/j.1469-0691.2011.03615.x

Keywords

candida; candidaemia; consensus; guidelines; therapy

Funding

  1. Pfizer (The Netherlands)
  2. Astellas
  3. Gilead
  4. Pfizer
  5. BioMerieux
  6. Merck
  7. Basilea
  8. Schering Plough
  9. Cephalon
  10. Biorad
  11. Wyeth
  12. Swedish Orphan
  13. Novartis
  14. Soria Melguizo SA
  15. Italfarmaco
  16. Novabiotics
  17. Johnson & Johnson Pharmaceutical Research
  18. Gilead Basilea
  19. Enzon
  20. Sanofi-Aventis Astellas
  21. Pliva

Ask authors/readers for more resources

This report discusses the present status of antifungal therapy and treatment options for candidaemia, considered by experts in the field in Europe. A conference of 26 experts from 13 European countries was held to discuss strategies for the treatment and prevention of invasive candidiasis, with the aim of providing a review on optimal management strategies. Published and unpublished comparative trials on antifungal therapy were analysed and discussed. Commonly asked questions about the management of candidaemia were selected, and possible responses to these questions were discussed. Panellists were then asked to respond to each question by using a touchpad answering system. After the initial conference, the viewpoint document has been reviewed and edited to include new insights and developments since the initial meeting. For many situations, consensus on treatment could not be reached, and the responses indicate that treatment is likely to be modified on a patient-to-patient basis, depending on factors such as degree of illness, prior exposure to azole antifungals, and the presence of potentially antifungal drug-resistant Candida species.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available